Choosing between NSAID and Arnica for topical treatment of hand osteoarthritis in a randomized, double-blind study

Rheumatology Clinic, 9004, St Gallen, Switzerland.
Rheumatology International (Impact Factor: 1.52). 05/2007; 27(6):585-91. DOI: 10.1007/s00296-007-0304-y
Source: PubMed


The use of topical preparations for symptom relief is common in osteoarthritis. The effects of ibuprofen (5%) and arnica (50 g tincture/100 g, DER 1:20), as gel preparations in patients with radiologically confirmed and symptomatically active osteoarthritis of interphalangeal joints of hands, were evaluated in a randomised, double-blind study in 204 patients, to ascertain differences in pain relief and hand function after 21 days' treatment. Diagnosis was according to established criteria; primary endpoints were pain intensity and hand function; statistical design was as per current regulatory guidelines for testing topical preparations. There were no differences between the two groups in pain and hand function improvements, or in any secondary end points evaluated. Adverse events were reported by six patients (6.1%) on ibuprofen and by five patients (4.8%) on arnica. Our results confirm that this preparation of arnica is not inferior to ibuprofen when treating osteoarthritis of hands.

Download full-text


Available from: Jörg Melzer,
    • "Capsaicin is a neuromodulator and has been recommended as ‘an add-on therapy for patients with persistent local pain and inadequate response or intolerance to other treatments’.[14] Lastly, Arnica is commonly recommended for external use for rheumatic muscle and joint problems, inflammation, and for symptomatic relief in OA of the hands[15] and knees.[1617] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Arthritis affects both the physical and psychological abilities of people in all walks of life. There are currently no recommended effective 'disease-modifying' remedies. Therapists and physicians are therefore exploring possible benefits from non-conventional therapeutic approaches. The purpose is to assess the changes in fitness and psychosocial outcomes of six doctor-referred patients as a result of participating in the I Can Move Again (ICMA) program. Six female participants diagnosed with arthritis were recruited from a local family practitioner. The subjects participated in a series of daily classes for 12 weeks including massage, mindfulness, bounce-back chairs, resistance chairs, aerobic and anaerobic training, rebounders, and whole body vibration platform Tai Chi. Demographic, psychosocial, and physical data were collected at the ICMA and at Y-Be-Fit (Provo, UT). Significant pre to post mean differences were found for sit-ups (F (1,8) =5.42 P =0.048), chair stand (F (1,10) =6.622 P =0.028), arm curl (F (1,10) =14.379 P =0.004), six-minute walk test distance (F (1,9)= 19.188 P=0.002), and speed (F,(1,8) =13.984 P =0.006), and rotation right (F (1,10) =8.921 P =0.014) and left (F (1,10) =11.373 P =0.007), in 27 of the 61-item questionnaire. The preliminary data on the six subjects lacked sufficient statistical power to detect the significant differences that could exist, thus committing a Type II error, but it is important to note an overall, substantial trend in improvement in the patients' physical outcomes and psychosocial perceptions associated with improvements in activities of daily living.
    Journal of Traditional and Complementary Medicine 04/2014; 4(2):99-107. DOI:10.4103/2225-4110.124364
  • Source
    • "Recent studies show that Echinacea has both anti-inflammatory and antiinfluenza effects [10]. Arnica montana has also been shown to possess anti-inflammatory and antimicrobial properties mediated by the presence of two compounds, namely thymol and helenalin [34] [35]. Thymol is capable of inhibiting elastase release from activated neutrophils, possibly reducing some of the collateral damage associated with inflammation [36] and inhibiting influenza A replication due to nonspecific inhibition of protein synthesis [37]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ekybion is a drug complex of 16 natural extracts and inorganic compounds designed to treat a variety of respiratory pathogens of bacterial and viral origin. It is licensed throughout Europe for the treatment of respiratory tract infections from equine parainfluenza type 3 and equine herpes virus type 1 in equine stables. The purpose of this paper was to test the efficacy of Ekybion on a well-developed animal model of influenza A infection and determine a mode of action. Experiments were performed with Balb/c mice infected with a lethal dose of influenza A/PR/8/34 H1N1 virus and treated with nebulized Ekybion every 8 h in a time-dependant or dose-dependant fashion. These experiments showed that mice treated prior to infection with Ekybion had a higher survival rates (~46%) compared with untreated animals (~0%). Paradoxically, these mice showed no significant difference in lung virus titer or weight loss. There was, however, a decrease in the level of GM-CSF, IL-6, and G-CSF cytokines in the lungs of Ekybion-treated, infected mice. It is possible that decreases in proinflammatory cytokines may have contributed to increased survivorship in Ekybion-treated influenza-infected mice.
    Evidence-based Complementary and Alternative Medicine 01/2011; 2011(1741-427X):192079. DOI:10.1155/2011/192079 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Le traitement médical de l’arthrose digitale comprend les mesures de prévention, les possibilités d’action par la rééducation, y compris les techniques d’orthétisation et la prise en charge médicamenteuse. Medical treatment of osteoarthritis of the fingers includes preventive measures, physiotherapy, including orthesis techniques and treatment with drugs.
    La Lettre de médecine physique et de réadaptation 06/2009; 25(2):112-116. DOI:10.1007/s11659-009-0130-6
Show more